Helixmith Co., Ltd
A biotech R&D company developing cell and gene therapies such as VM202 alongside natural-product-derived new drugs.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1996 and listed on KOSDAQ in 2005, Helixmith is a biotech company focused on new drug R&D. Its pipeline includes the cell and gene therapy VM202 (diabetic foot ulcer, critical limb ischemia, ALS, CMT), NM301 (ALS), CX801 (colorectal cancer), CX804 (ovarian cancer), and VM507 (kidney disease), while natural-product ingredients PG102, HX106, and HX107 have received individual-type functional food ingredient recognition and are used in its health functional food and cosmetics B2B business. VM202's U.S. Phase 3 trial was terminated early while its China Phase 3 trial was completed and is pursuing marketing approval; the ALS indication completed U.S./Korea Phase 2 and the CMT indication completed Korea Phase 1, and a research team of 16 (4 PhDs, 11 master's-level researchers) has conducted government R&D projects since 1999.
Products & technology
- PG102Improvement of immune hypersensitivity reactions
- HX106Memory improvement
- HX107Suppression of postprandial blood glucose rise
Clinical trials
data.go.kr5 MFDS clinical trial authorisations · 2012–2022 (Phase 2a 2 · Phase 2 2 · Phase 1/2a 1)
- Phase 2a엔젠시스(Engensis),VM2022022-04-18
1 trial site
- Phase 2a엔젠시스(Engensis),VM2022021-06-16
1 trial site
- Phase 1/2a엔젠시스(Engensis),VM2022020-04-20
1 trial site
- Phase 2엔젠시스(Engensis),VM2022016-07-29
3 trial sites
- Phase 2엔젠시스(Engensis),VM2022012-04-02
4 trial sites
R&D and key agreements
Source: DART corporate disclosureVM202 · 당뇨병성 허혈성 족부궤양(PAD/NHU), 중증하지허혈(PAD/CLI) · 미국 임상 3상 조기 종료 / 중국 임상 3상 완료·시판허가 진행 · Plasmid DNA-based cell and gene therapy pipeline
VM202 · 근위축성 측삭경화증(ALS, 루게릭병) · 미국/한국 임상 2상 완료
VM202 · 샤르코-마리-투스병(CMT) · 한국 임상 1상 완료
NM301 · 근위축성 측삭경화증(ALS) · 후보물질 발굴 혹은 전임상
CX801 · 대장암 · 전임상
CX804 · 난소암 · 전임상
VM507 · 신장질환 · 전임상
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition